189 related articles for article (PubMed ID: 33247204)
1. RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia.
Koschut D; Ray D; Li Z; Giarin E; Groet J; Alić I; Kham SK; Chng WJ; Ariffin H; Weinstock DM; Yeoh AE; Basso G; Nižetić D
Oncogene; 2021 Jan; 40(4):746-762. PubMed ID: 33247204
[TBL] [Abstract][Full Text] [Related]
2. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations.
Nikolaev SI; Garieri M; Santoni F; Falconnet E; Ribaux P; Guipponi M; Murray A; Groet J; Giarin E; Basso G; Nizetic D; Antonarakis SE
Nat Commun; 2014 Aug; 5():4654. PubMed ID: 25105841
[TBL] [Abstract][Full Text] [Related]
3. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
4. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
[TBL] [Abstract][Full Text] [Related]
5. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
[TBL] [Abstract][Full Text] [Related]
6. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
Tasian SK; Doral MY; Borowitz MJ; Wood BL; Chen IM; Harvey RC; Gastier-Foster JM; Willman CL; Hunger SP; Mullighan CG; Loh ML
Blood; 2012 Jul; 120(4):833-42. PubMed ID: 22685175
[TBL] [Abstract][Full Text] [Related]
7. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
[TBL] [Abstract][Full Text] [Related]
8. Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.
Hanada I; Terui K; Ikeda F; Toki T; Kanezaki R; Sato T; Kamio T; Kudo K; Sasaki S; Takahashi Y; Hayashi Y; Inukai T; Kojima S; Koike K; Kosaka Y; Kobayashi M; Imaizumi M; Mitsui T; Hori H; Hara J; Horibe K; Nagai J; Goto H; Ito E
Genes Chromosomes Cancer; 2014 Nov; 53(11):902-10. PubMed ID: 25044358
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
[TBL] [Abstract][Full Text] [Related]
10. CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.
Roll JD; Reuther GW
Cancer Res; 2010 Oct; 70(19):7347-52. PubMed ID: 20807819
[TBL] [Abstract][Full Text] [Related]
11. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.
van Bodegom D; Zhong J; Kopp N; Dutta C; Kim MS; Bird L; Weigert O; Tyner J; Pandey A; Yoda A; Weinstock DM
Blood; 2012 Oct; 120(14):2853-63. PubMed ID: 22915648
[TBL] [Abstract][Full Text] [Related]
12. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
13. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.
Buitenkamp TD; Pieters R; Gallimore NE; van der Veer A; Meijerink JP; Beverloo HB; Zimmermann M; de Haas V; Richards SM; Vora AJ; Mitchell CD; Russell LJ; Schwab C; Harrison CJ; Moorman AV; van den Heuvel-Eibrink MM; den Boer ML; Zwaan CM
Leukemia; 2012 Oct; 26(10):2204-11. PubMed ID: 22441210
[TBL] [Abstract][Full Text] [Related]
14. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.
Kearney L; Gonzalez De Castro D; Yeung J; Procter J; Horsley SW; Eguchi-Ishimae M; Bateman CM; Anderson K; Chaplin T; Young BD; Harrison CJ; Kempski H; So CW; Ford AM; Greaves M
Blood; 2009 Jan; 113(3):646-8. PubMed ID: 18927438
[TBL] [Abstract][Full Text] [Related]
15. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.
Jain N; Roberts KG; Jabbour E; Patel K; Eterovic AK; Chen K; Zweidler-McKay P; Lu X; Fawcett G; Wang SA; Konoplev S; Harvey RC; Chen IM; Payne-Turner D; Valentine M; Thomas D; Garcia-Manero G; Ravandi F; Cortes J; Kornblau S; O'Brien S; Pierce S; Jorgensen J; Shaw KR; Willman CL; Mullighan CG; Kantarjian H; Konopleva M
Blood; 2017 Feb; 129(5):572-581. PubMed ID: 27919910
[TBL] [Abstract][Full Text] [Related]
16. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Paulsson K; Horvat A; Strömbeck B; Nilsson F; Heldrup J; Behrendtz M; Forestier E; Andersson A; Fioretos T; Johansson B
Genes Chromosomes Cancer; 2008 Jan; 47(1):26-33. PubMed ID: 17910045
[TBL] [Abstract][Full Text] [Related]
17. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
[TBL] [Abstract][Full Text] [Related]
18. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
Kim SK; Knight DA; Jones LR; Vervoort S; Ng AP; Seymour JF; Bradner JE; Waibel M; Kats L; Johnstone RW
Genes Dev; 2018 Jun; 32(11-12):849-864. PubMed ID: 29907650
[TBL] [Abstract][Full Text] [Related]
19. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
Harvey RC; Mullighan CG; Chen IM; Wharton W; Mikhail FM; Carroll AJ; Kang H; Liu W; Dobbin KK; Smith MA; Carroll WL; Devidas M; Bowman WP; Camitta BM; Reaman GH; Hunger SP; Downing JR; Willman CL
Blood; 2010 Jul; 115(26):5312-21. PubMed ID: 20139093
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of CRLF2 overexpression and JAK2 mutation in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia.
Hassan NM; Abdellateif MS; Radwan EM; Hameed SA; Desouky EDE; Kamel MM; Gameel AM
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e376-e385. PubMed ID: 34987014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
